Abstract
Tauopathies, including Alzheimers disease, are neurodegenerative diseases characterized by the deposition of hyperphosphorylated tau protein in the central nervous system, and are the major cause of dementia in later life. Considerable advances have been made in developing mouse models that recapitulate, to varying extents, the development of human tau pathology, and the learning and memory deficits characteristic of some tauopathies. Furthermore, such models have been used to show promising disease-modifying effects in pre-clinical testing of new therapeutics. Various strategies have been utilised to generate mouse models of tauopathies. Some of the most enlightening models developed to date either constitutively or inducibly express pathogenic tau mutations. These animals have been instrumental in defining critical disease-related mechanisms, including the observation that tangles are not the toxic form of tau in disease. Here, we discuss the strengths and weaknesses of well characterised transgenic models that emulate human tauopathy, and include a comprehensive listing of the main phenotypic characteristics of all reported tau transgenic rodents. We summarise the use of tau mice for the development and evaluation of new therapeutic approaches, and their utility in identifying novel drug targets. In addition, we review the parameters to be considered in the development of the next generation of rodent models of tauopathy, aimed at further increasing our understanding of disease aetiology and in evaluating novel treatments.
Keywords: Tauopathy, neurofibrillary tangle, kinase, transgenic model, therapeutic, phosphorylation, phenotype, microtubule-associated protein tau, neurodegeneration, Alzheimer's disease
CNS & Neurological Disorders - Drug Targets
Title: Transgenic Mouse Models of Tauopathy in Drug Discovery
Volume: 9 Issue: 4
Author(s): W. Noble, D.P. Hanger and J.-M. Gallo
Affiliation:
Keywords: Tauopathy, neurofibrillary tangle, kinase, transgenic model, therapeutic, phosphorylation, phenotype, microtubule-associated protein tau, neurodegeneration, Alzheimer's disease
Abstract: Tauopathies, including Alzheimers disease, are neurodegenerative diseases characterized by the deposition of hyperphosphorylated tau protein in the central nervous system, and are the major cause of dementia in later life. Considerable advances have been made in developing mouse models that recapitulate, to varying extents, the development of human tau pathology, and the learning and memory deficits characteristic of some tauopathies. Furthermore, such models have been used to show promising disease-modifying effects in pre-clinical testing of new therapeutics. Various strategies have been utilised to generate mouse models of tauopathies. Some of the most enlightening models developed to date either constitutively or inducibly express pathogenic tau mutations. These animals have been instrumental in defining critical disease-related mechanisms, including the observation that tangles are not the toxic form of tau in disease. Here, we discuss the strengths and weaknesses of well characterised transgenic models that emulate human tauopathy, and include a comprehensive listing of the main phenotypic characteristics of all reported tau transgenic rodents. We summarise the use of tau mice for the development and evaluation of new therapeutic approaches, and their utility in identifying novel drug targets. In addition, we review the parameters to be considered in the development of the next generation of rodent models of tauopathy, aimed at further increasing our understanding of disease aetiology and in evaluating novel treatments.
Export Options
About this article
Cite this article as:
Noble W., Hanger D.P. and Gallo J.-M., Transgenic Mouse Models of Tauopathy in Drug Discovery, CNS & Neurological Disorders - Drug Targets 2010; 9 (4) . https://dx.doi.org/10.2174/187152710791556131
DOI https://dx.doi.org/10.2174/187152710791556131 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective
Current Stem Cell Research & Therapy Hippocampal Subfield Atrophies in Converted and Not-Converted Mild Cognitive Impairments Patients by a Markov Random Fields Algorithm
Current Alzheimer Research Functional Multipotency of Stem Cells: A Conceptual Review of Neurotrophic Factor-Based Evidence and Its Role in Translational Research
Current Neuropharmacology Editorial (Thematic Issue: Medication Management for People with Dementia or Cognitive Impairment)
Current Clinical Pharmacology Advanced Tools of Regenerative Medicine for Neurodegenerative Diseases
Recent Patents on Regenerative Medicine Homocysteine and Hyperhomocysteinaemia
Current Medicinal Chemistry Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists
Current Alzheimer Research Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation
CNS & Neurological Disorders - Drug Targets Models for Non-Alcoholic Fatty Liver Disease: A Link with Vascular Risk
Current Pharmaceutical Design Assessment of Persistent, Bioaccumulative and Toxic Organic Environmental Pollutants in Liver and Adipose Tissue of Alzheimer’s Disease Patients and Age-matched Controls
Current Alzheimer Research Small Molecules that Promote Neurogenesis in vitro
Recent Patents on CNS Drug Discovery (Discontinued) What is Tobacco Smoke? Sociocultural Dimensions of the Association with Cardiovascular Risk
Current Pharmaceutical Design Reversal in Cognition Impairments, Cholinergic Dysfunction, and Cerebral Oxidative Stress Through the Modulation of Ryanodine Receptors (RyRs) and Cysteinyl Leukotriene-1 (CysLT1) Receptors
Current Neurovascular Research Risk Factors of Alzheimers Disease Among Iranian Population
Current Alzheimer Research Ethnobotanical Treatment Strategies Against Alzheimers Disease
Current Alzheimer Research Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Genomics and Pharmacogenomics of Brain Disorders
Current Pharmaceutical Biotechnology Multiple Defects in Energy Metabolism in Alzheimers Disease
Current Drug Targets Neurogenesis in the Adult Brain: Implications for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets